Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | PAK4 | O96013 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21508478 | 0.79 | HTT (0.34) | HTTKMT2AALDH1A1NPC1DYRK1A | |
| SCHEMBL2067182 | 0.79 | GABRA1 (0.36) | HTTKMT2AALDH1A1NPC1DYRK1A | |
| SCHEMBL22518949 | 0.77 | KMT2A (0.35) | HTTKMT2AALDH1A1NPC1DYRK1A | |
| SCHEMBL2066697 | 0.77 | SMN1; SMN2 (0.36) | HTTKMT2AALDH1A1NPC1DYRK1A | |
| SCHEMBL27688260 | 0.77 | NOS3 (0.35) | NPC1RPS6KA3 | |
| SCHEMBL856790 | 0.76 | SLC22A12 (0.44) | HTTKMT2AALDH1A1NPC1 | |
| SCHEMBL25147686 | 0.75 | GRM4 (0.43) | HTTKMT2AALDH1A1NPC1JAK2 | |
| SCHEMBL12722223 | 0.75 | KMT2A (0.54) | HTTKMT2AALDH1A1NPC1DYRK1A | |
| SCHEMBL7995393 | 0.75 | KMT2A (0.34) | HTTKMT2AALDH1A1DYRK1AAURKA | |
| SCHEMBL29705465 | 0.75 | KMT2A (0.54) | HTTKMT2AALDH1A1NPC1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3200787-B1 | INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME (US) | 2019-09-04 | — | — | EP | disclosed |
| EP-3200787-B1 | INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME (US) | 2019-09-04 | — | — | EP | disclosed |
| US-9969749-B2 | Inhibitors of IRAK4 activity | MERCK SHARP & DOHME CORP. (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170275297-A1 | INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2017-09-28 | — | — | US | disclosed |
| US-20170275297-A1 | INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2017-09-28 | — | — | US | disclosed |
| EP-3200787-A1 | INHIBITORS OF IRAK4 ACTIVITY | Merck Sharp & Dohme Corp. (US) | 2017-08-09 | — | — | EP | disclosed |
| WO-2016053771-A1 | INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2016-04-07 | — | — | WO | disclosed |
| US-20140005163-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES | NOVARTIS AG (CH) | 2014-01-02 | — | — | US | disclosed |
| US-8476294-B2 | 1H-imidazo[4,5-c]quinolinone derivatives | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| US-8476294-B2 | 1H-imidazo[4,5-c]quinolinone derivatives | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| US-8476294-B2 | 1H-imidazo[4,5-c]quinolinone derivatives | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG | 2010-12-16 | — | — | US | disclosed |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG | 2010-12-16 | — | — | US | disclosed |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275297-A1 | INHIBITORS OF IRAK4 ACTIVITY | IRAK4, IRAK2, IRAK1 | HTT 3983/4885KMT2A 529/4885ALDH1A1 2734/4885 |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | PRKCA, CSNK1A1, ABL1 | HTT 1605/4885KMT2A 1019/4885ALDH1A1 2405/4885 |
| US-20140005163-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES | PRKCA, CSNK1A1, ABL1 | HTT 1605/4885KMT2A 1019/4885ALDH1A1 2405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.